Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change.

Tsai KK, Khurana N, McCalmont T, Daud A, Bastian B, Yeh I.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):778-783. doi: 10.6004/jnccn.2019.7313.

PMID:
31319387
2.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
3.

Association between walking time spent and high sensitivity C-reactive protein level among obese women.

Daud A, Sedek SSHAB, Shahadan SZ.

Enferm Clin. 2019 Jun 24. pii: S1130-8621(19)30106-8. doi: 10.1016/j.enfcli.2019.04.015. [Epub ahead of print] English, Spanish.

PMID:
31248730
4.

Factors Contributing to Sharp Waste Disposal at Health Care Facility Among Diabetic Patients in North-East Peninsular Malaysia.

Hasan UA, Mohd Hairon S, Yaacob NM, Daud A, Abdul Hamid A, Hassan N, Ariffin MF, Yi Vun L.

Int J Environ Res Public Health. 2019 Jun 26;16(13). pii: E2251. doi: 10.3390/ijerph16132251.

5.

Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.

Oglesby A, Algazi AP, Daud AI.

Am J Clin Dermatol. 2019 Jun 21. doi: 10.1007/s40257-019-00452-8. [Epub ahead of print] Review.

PMID:
31228012
6.

Leptospirosis and its prevention: knowledge, attitude and practice of urban community in Selangor, Malaysia.

Abdullah NM, Mohammad WMZW, Shafei MN, Sukeri S, Idris Z, Arifin WN, Nozmi N, Saudi SNS, Samsudin S, Zainudin AW, Hamat RA, Ibrahim R, Masri SN, Saliluddin SM, Daud A, Osman M, Jamaluddin TZMT.

BMC Public Health. 2019 May 22;19(1):628. doi: 10.1186/s12889-019-6981-0.

7.

Occupational and Environmental Risk Factors Influencing the Inducement of Erythema among Nigerian Laboratory University Workers with Multiple Chemical Exposures.

Reuben U, Ismail AF, Ahmad AL, Maina HM, Daud A.

Int J Environ Res Public Health. 2019 Apr 13;16(8). pii: E1334. doi: 10.3390/ijerph16081334.

8.

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.

Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF.

Cell. 2019 Apr 18;177(3):556-571.e16. doi: 10.1016/j.cell.2019.02.005. Epub 2019 Apr 4.

PMID:
30955881
9.

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization.

Ho B, Bhagat H, Schwartz JJ, Atiemo K, Daud A, Kang R, Montag SE, Zhao L, Lee E, Skaro AI, Ladner DP.

Adv Ther. 2019 Jun;36(6):1465-1479. doi: 10.1007/s12325-019-00904-x. Epub 2019 Apr 2.

PMID:
30941724
10.

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.

Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A.

Pigment Cell Melanoma Res. 2019 Jul;32(4):603-606. doi: 10.1111/pcmr.12777. Epub 2019 Apr 13. No abstract available.

PMID:
30801911
11.

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L.

Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006. Epub 2019 Feb 5.

PMID:
30737146
12.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
13.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.

14.

Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.

Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA.

Front Med (Lausanne). 2018 Dec 12;5:351. doi: 10.3389/fmed.2018.00351. eCollection 2018. Review.

15.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ.

Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.

PMID:
30552023
16.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340. No abstract available.

PMID:
30510087
17.

Seroprevalence and distribution of leptospirosis serovars among wet market workers in northeastern, Malaysia: a cross sectional study.

Rahman MHAA, Hairon SM, Hamat RA, Jamaluddin TZMT, Shafei MN, Idris N, Osman M, Sukeri S, Wahab ZA, Mohammad WMZW, Idris Z, Daud A.

BMC Infect Dis. 2018 Nov 14;18(1):569. doi: 10.1186/s12879-018-3470-5.

18.

Microvascular Loss and Diastolic Dysfunction in Severe Symptomatic Cardiac Allograft Vasculopathy.

Daud A, Xu D, Revelo MP, Shah Z, Drakos SG, Dranow E, Stoddard G, Kfoury AG, Hammond MEH, Nativi-Nicolau J, Alharethi R, Miller DV, Gilbert EM, Wever-Pinzon O, McKellar SH, Afshar K, Khan F, Fang JC, Selzman CH, Stehlik J.

Circ Heart Fail. 2018 Aug;11(8):e004759. doi: 10.1161/CIRCHEARTFAILURE.117.004759.

PMID:
30354559
19.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.

Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M.

Br J Cancer. 2018 Sep;119(6):670-674. doi: 10.1038/s41416-018-0207-6. Epub 2018 Sep 11.

PMID:
30202085
20.

Prevalence and association between triglyceride level and lifestyle factors among Malay obese class I and II adults.

Daud A, Shahadan SZ, Ibrahim M, Lokman Md Isa M, Deraman S.

Enferm Clin. 2018 Feb - Jun;28 Suppl 1:310-315. doi: 10.1016/S1130-8621(18)30176-1. English, Spanish.

PMID:
30115355
21.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

22.

Immunotherapy for melanoma.

Cuevas LM, Daud AI.

Semin Cutan Med Surg. 2018 Jun;37(2):127-131. doi: 10.12788/j.sder.2018.028.

PMID:
30040090
23.

Melanocytic Neoplasms, Introduction.

Daud AI.

Semin Cutan Med Surg. 2018 Jun;37(2):87. doi: 10.12788/j.sder.2018.030. No abstract available.

PMID:
30040084
24.

Leptospirosis seropositivity and its serovars among cattle in Northeastern Malaysia.

Daud A, Fuzi NMHM, Arshad MM, Kamarudin S, Mohammad WMZW, Amran F, Ismail N.

Vet World. 2018 Jun;11(6):840-844. doi: 10.14202/vetworld.2018.840-844. Epub 2018 Jun 23.

25.

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.

Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S.

Sci Rep. 2018 Jul 19;8(1):10902. doi: 10.1038/s41598-018-27643-3.

26.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
27.

A qualitative exploration of the misconceptions, knowledge gaps and constructs of leptospirosis among rural and urban communities in Malaysia.

Sukeri S, Idris Z, Zahiruddin WM, Shafei MN, Idris N, Hamat RA, Jamaluddin TZT, Osman M, Wahab ZA, Daud A.

PLoS One. 2018 Jul 18;13(7):e0200871. doi: 10.1371/journal.pone.0200871. eCollection 2018.

28.

Leptospirosis Health Intervention Module Effect on Knowledge, Attitude, Belief, and Practice among Wet Market Workers in Northeastern Malaysia: An Intervention Study.

Rahman MHAA, Hairon SM, Hamat RA, Jamaluddin TZMT, Shafei MN, Idris N, Osman M, Sukeri S, Wahab ZA, Mohammad WMZW, Idris Z, Daud A.

Int J Environ Res Public Health. 2018 Jul 3;15(7). pii: E1396. doi: 10.3390/ijerph15071396.

29.

A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.

Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF.

Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25.

30.

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma.

Daud AI.

Lancet Oncol. 2018 Jul;19(7):852-853. doi: 10.1016/S1470-2045(18)30353-X. Epub 2018 Jun 13. No abstract available.

PMID:
29908989
31.
32.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6098.

PMID:
29685882
33.

Leptospirosis and Workplace Environmental Risk Factors among Cattle Farmers in Northeastern Malaysia.

Daud AB, Mohd Fuzi NMH, Wan Mohammad WMZ, Amran F, Ismail N, Arshad MM, Kamarudin S.

Int J Occup Environ Med. 2018 Apr;9(2):88-96. doi: 10.15171/ijoem.2018.1164.

34.

Fracture risk prediction in post-menopausal women with osteopenia and osteoporosis: preliminary findings.

Nik Mohd Hatta NNK, Lokman M, Said N M, Daud A, Ibrahim M, Sharifudin MA, Deraman S.

Enferm Clin. 2018 Feb;28 Suppl 1:232-235. doi: 10.1016/S1130-8621(18)30074-3. English, Spanish.

PMID:
29650194
35.

Relationship between levels of thyroid stimulating hormone, age, and gender, with symptoms of depression among patients with thyroid disorders as measured by the Depression Anxiety Stress Scale 21 (DASS-21).

Saidi S, Iliani Jaafar SN, Daud A, Musa R, Nik Ahmad NNF.

Enferm Clin. 2018 Feb;28 Suppl 1:180-183. doi: 10.1016/S1130-8621(18)30063-9. English, Spanish.

PMID:
29650181
36.

Low Levels of Knowledge, Attitudes and Preventive Practices on Leptospirosis among a Rural Community in Hulu Langat District, Selangor, Malaysia.

Nozmi N, Samsudin S, Sukeri S, Shafei MN, Wan Mohd WMZ, Idris Z, Arifin WN, Idris N, Saudi SNS, Abdullah NM, Abdul Wahab Z, Tengku Jamaluddin TZM, Abd Rahman H, Masri SN, Daud A, Osman M, Awang Hamat R.

Int J Environ Res Public Health. 2018 Apr 6;15(4). pii: E693. doi: 10.3390/ijerph15040693.

37.

Should Undergraduate Lectures be Compulsory? The Views of Dental and Medical Students from a UK University.

Daud A, Bagria A, Shah K, Puryer J.

Dent J (Basel). 2017 Mar 31;5(2). pii: E15. doi: 10.3390/dj5020015.

38.

The gut microbiota and immune checkpoint inhibitors.

Humphries A, Daud A.

Hum Vaccin Immunother. 2018;14(9):2178-2182. doi: 10.1080/21645515.2018.1442970. Epub 2018 Apr 9.

39.

Revisiting RECIST: the case of treatment beyond progression.

Daud AI.

Lancet Oncol. 2018 Feb;19(2):157-159. doi: 10.1016/S1470-2045(18)30007-X. Epub 2018 Jan 18. No abstract available.

PMID:
29361472
40.

A randomised controlled study on the use of finishing and polishing systems on different resin composites using 3D contact optical profilometry and scanning electron microscopy.

Daud A, Gray G, Lynch CD, Wilson NHF, Blum IR.

J Dent. 2018 Apr;71:25-30. doi: 10.1016/j.jdent.2018.01.008. Epub 2018 Jan 31.

PMID:
29360492
41.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.

PMID:
29283791
42.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
43.

Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid).

Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH, Pierce RH, Gargosky S, Daud A, Algazi A.

Immunotherapy. 2017 Dec;9(16):1309-1321. doi: 10.2217/imt-2017-0096. Epub 2017 Oct 24.

44.

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI.

Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20.

45.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

46.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT.

J Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9.

PMID:
28991513
47.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.

PMID:
28961465
48.

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.

Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A.

Pigment Cell Melanoma Res. 2018 Jan;31(1):110-114. doi: 10.1111/pcmr.12644. Epub 2017 Nov 2.

PMID:
28921907
49.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
50.

Association Between Body Mass Index and Cardiometabolic Risks Among Malay Obese Adults.

Daud A, Shahadan SZ.

Clin Nurs Res. 2019 Feb;28(2):202-216. doi: 10.1177/1054773817724041. Epub 2017 Aug 6.

PMID:
28782381

Supplemental Content

Support Center